18 results about "Premature ageing" patented technology

Systems, methods, and instrumentalities are described herein for identifying a user (e.g., a consumer) at risk for premature aging through dynamic facial imaging assessment. For example, a computing system may receive video data. The video data may be, or may include, one or more frames associated with the face of the user. The computing device may identify a frame from the video data. The computing device may determine a number of baseline wrinkles associated with the first state. The computing device may determine a number of dissipating wrinkles associated with the second state (e.g., a duration after the peak and relaxation of facial expression). Based on the number of baseline wrinkles and the number of dissipating wrinkles, the computing device may calculate a number of residual wrinkles between the first state and the second state. The computing device may map the number of residual wrinkles to the consumer risk for premature aging.

Materials and methods for regenerating senescent cells are provided. Aging cells are transduced with viral vectors to express Oct4, Sox2 and Klf4 proteins for partial cell reprogramming and to express dominant negative NF [kappa] BIA proteins to inhibit secretion phenotypes associated with aging. The materials and methods provided may be used to treat signs and symptoms of premature senility syndrome, premature aging, or natural aging, or to regenerate tissue in a subject experiencing premature aging or having an age-related disease.

WATER-SOLUBLE EXTRACT FROM A PLANT OF THE PRUNUS SPECIES TO PREVENT THE DELETE EFFECTS OF THE EXPOSOME. The present invention relates to the use of a flower extract from a plant of the Rosaceae family and the Prunus genus, or a composition thereof, to protect the skin from the deleterious effects of the exposome, including disruption of the barrier function, neurogenic inflammation, irritation, and oxidative stress. The invention is thus intended to prevent the clinical signs of premature aging, including the appearance of hyperpigmentation spots responsible for loss of skin tone uniformity and skin hyperreactivity.

The application discloses application of cell endogenous metabolites in preparation of medicines for treating and / or preventing aging. The cell endogenous metabolites are any one or combination of phosphocreatine, hypotaurine and / or phosphoethanolamine. The application finds that phosphocreatine, hypotaurine and phosphoethanolamine can effectively restore cell growth, reduce cell SA-beta-Gal staining intensity, improve cell mitochondrial function and increase ATP yield, restore cell mitochondrial membrane potential, alleviate damage caused by cell oxidative stress and premature aging, and also prolong the life of nematodes and restore exercise capacity in the middle of aging. Meanwhile, the three metabolites have a synergistic effect, and by adjusting the matching concentration of the three metabolites, the same cell protection effect can be achieved by mixed administration. Since the endogenous metabolites are accurate, efficient and safe, the three cell endogenous metabolites provided by the application can be used for preparing anti-aging medicines.

This invention provides a method, system, and storage medium for assessing the vascular physiological age of hypertensive patients, belonging to the field of intelligent medical technology. The method includes: acquiring assessment data to characterize the vascular state of hypertensive patients, and constructing a sequence of vascular feature parameters based on the assessment data; inputting the vascular feature parameter sequence into a pre-trained vascular physiological age prediction model to perform feature learning processing, and outputting vascular physiological age parameters; inputting the vascular physiological age parameters into a time-series analysis model to perform trend analysis processing, generating longitudinal aging feature parameters; judging the degree of premature aging of blood vessels based on the longitudinal aging feature parameters, and outputting the vascular physiological age assessment result of the hypertensive patient. This invention achieves reliable processing of the vascular physiological age and stable assessment of the degree of premature aging for individual hypertensive patients.

The present invention relates to a method for identifying the aging degree of a subject or a tissue or organ thereof, and for evaluating the effect of anti-aging interventions. Specifically, provided is a method for identifying the aging degree of a subject or a cell, tissue or organ thereof, or for evaluating the biological age of the subject or diagnosing premature aging disorders, which method predicts the aging status of a tissue or organ of a subject on the basis of the levels of DNA methylation, gene transcripts, proteins or metabolites. The present invention further relates to the use of metformin in the preparation of a drug for treating, preventing or delaying aging-related diseases or conditions in primates, preferably humans.

The invention discloses a premature ovarian failure rat animal model building method based on enterovirus group transplantation, and particularly relates to the technical field of animal model building. According to the invention, the enterovirus group of a premature ovarian failure patient is subjected to in-vitro extraction and purification, and then is transplanted into a female rat, so that a new experimental model is provided for researching the interaction between the enterovirus group and the premature ovarian failure; meanwhile, a new way is opened up for further revealing the research on the complex relation between intestinal microorganisms and female reproductive health. In addition, the model is expected to provide an experimental basis for developing a novel treatment strategy for premature ovarian failure. The method aims to deeply explore the relationship between the enterovirus / bacteriophage group and female reproductive system diseases, especially premature ovarian failure.

The invention belongs to the field of biological medicine, and relates to a preparation method of a premature senility animal model. The invention provides an RNA (Ribonucleic Acid), wherein the RNA is selected from any sequence shown in SEQ ID NO: 1-3. The RNA is sgRNA, the sgRNA can specifically target the Lmna c.1827 site, and the Lmna c.1827 site is edited by combining a base editing protein, so that the premature senility animal model is successfully obtained. And a powerful model animal model tool is provided for deeply researching the pathogenesis of the premature senility and finding a potential treatment method.

The present invention discloses a promoter for regulating the premature aging trait of Chinese cabbage leaves and its application. The premature aging gene of the present invention is a newly identified control gene, and its promoter is responsible for regulating the occurrence of premature aging traits, providing a new method for studying the molecular mechanism of premature aging and breeding.

Provided are materials and methods for rejuvenating senescent cells. Senescent cells are transduced with a viral vector to express Oct4 and Sox2 proteins for partial cell reprogramming and / or to suppress a senescence-associated secretory phenotype. The materials and methods provided can be used to treat progeria syndrome, signs and symptoms of premature aging or natural aging or to rejuvenate tissue in subjects experiencing premature aging or having an agerelated disease.

Systems, methods, and instrumentalities are described herein for identifying a user (e.g., a consumer) at risk for premature aging through dynamic facial imaging assessment. For example, a computing system may receive video data. The video data may be, or may include, one or more frames associated with the face of the user. The computing device may identify a frame from the video data. The computing device may determine a number of baseline wrinkles associated with the first state. The computing device may determine a number of dissipating wrinkles associated with the second state (e.g., a duration after the peak and relaxation of facial expression). Based on the number of baseline wrinkles and the number of dissipating wrinkles, the computing device may calculate a number of residual wrinkles between the first state and the second state. The computing device may map the number of residual wrinkles to the consumer risk for premature aging.

The invention belongs to the field of disease diagnosis, and discloses application of AQP1 as a depression-premature ovarian failure co-disease marker. PPI analysis shows that the AQP1 is located at a high connection center and is enriched in functional modules such as water channel activity, transmembrane transport, cell membrane structure and the like. GO enrichment analysis further shows that AQP1 mainly participates in water transport and transmembrane signal regulation and is closely related to the hypothalamic-pituitary-ovary (HPO) axis and brain tissue homeostasis. AQP1 expression is in significant negative correlation with POF, has no multi-effect and heterogeneity interference, and supports the potential causal effect of the POF. The AQP1 not only shows differential expression in the depression-ovarian function premature senility co-disease, but also shows dynamic change consistent with pathological severity in an MISS model simulating the depression-ovarian function premature senility co-disease state, and the AQP1 protein is related to the depression-ovarian function premature senility co-disease. By detecting the expression condition of the AQP1 protein of a subject, the depression-premature ovarian failure co-disease condition can be well determined, and an objective biomarker is provided for MDD diagnosis.

The application provides a premature aging mouse and application thereof. The application also provides a construction method of the premature aging mouse. Compared with a wild type mouse, the Lmna gene of the premature aging mouse has a mutation of A604V. The application also provides a nucleic acid molecule encoding Lmna, wherein the nucleic acid molecule corresponds to a mutation of C to T at position 1811 and a mutation of C to T at position 1827 in the nucleotide sequence shown in SEQ ID NO:1. The premature aging mouse constructed by the application has an aging phenotype at about 3 months after birth, and the life span can reach about 5-12 months, the window period for research is prolonged, and the practicability of the premature aging mouse is further increased.

The invention belongs to the technical field of biology, and particularly discloses application of dihydromyricetin in preparation of an inflammatory factor inhibitor for regulating immune homeostasis, the inhibitor comprises a medicine for reducing the content of inflammatory factors in cells and / or the content of cyclin, and specifically comprises dihydromyricetin; the inflammatory factors comprise Il8, Il1-alpha, Il1-beta and Il6. According to the application, by establishing a H2O2 induced human skin fibroblast premature senility model and a H2O2 induced mouse fibroblast premature senility model, the dihydromyricetin is found to be used as an inhibitor, so that overexpression of inflammatory factors including Il8, Il1-alpha, Il1-beta and Il6 can be effectively reduced, expression of cyclin P16 is also reduced, and the inflammatory factors such as inflammatory factors including Il8, Il1-alpha, Il1-beta and Il6 can be effectively inhibited. The anti-aging and anti-inflammatory effects are effectively achieved in mammals, and the immune homeostasis is maintained.

The application discloses a Caenorhabditis elegans disease model and a construction method and application thereof, and particularly relates to a Caenorhabditis elegans disease model for neurodegenerative diseases, which comprises Caenorhabditis elegans, wherein a fragment of NOTCH2NLC GGC is overexpressed in the Caenorhabditis elegans, the sequence of the fragment is shown as SEQ ID NO. 1, and the neurodegenerative diseases include NIID. The application overcomes the difficulty of cloning GGC repeat sequences, successfully overexpresses 100 GGC repeat sequences of a human NOTCH2NLC gene in Caenorhabditis elegans, and shows similar behavior disorders and premature aging symptoms to human NIID diseases. The model is a good animal model for studying the pathogenic mechanism of GGC repeat sequences of the NOTCH2NLC gene and drug screening.

The application discloses a polypeptide UPCP and application thereof in preparation of anti-aging products. The polypeptide UPCP provided by the application has an amino acid sequence of sequence 4 in the sequence list. The polypeptide is applied in preparation of products with any one of the following functions: 1) treating children's premature aging; 2) delaying physiological aging of mammals or cells thereof; 3) improving premature aging of mammals; the improvement of premature aging of mammals is embodied in delaying premature aging of mammals; 4) improving body weight of premature aging animals; the improvement of body weight of premature aging animals is embodied in increasing body weight of premature aging animals; 5) relieving motor dysfunction of premature aging animals; 6) prolonging survival period of premature aging animals, etc. The application develops a specific peptide (UPCP) which can inhibit HGPS cell aging, improve aging characteristics of HGPS premature aging mice and prolong survival period, and provides a new strategy for treatment of HGPS.

The diagnostic procedure for premature aging of a grape-based alcoholic beverage susceptible to premature aging involves taking a sample of the alcoholic beverage, which is divided into three parts. The first part is subjected to chemical analysis to determine the concentration of a predetermined characteristic marker correlated with premature aging. The second part is subjected to analysis to determine a value for at least one antioxidant concentration. The third part is subjected to accelerated aging corresponding to natural aging for a duration Δt, then to chemical analysis to determine a value for the predetermined characteristic marker correlated with premature aging. A parameter representative of premature aging is then determined from these values. (See Figure 1 for abbreviations.)